Payment overview · 2025
General Payments
$732.17
32 reported records · 12 companies
Healthcare provider profile · identity verified
Robert Powell, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SOUTH HILL, VA · NPI 1104824382
Verified facts
What the public records show
CMS Open Payments records show Robert Powell, CNP received $732.17 in general payments during 2025 across 32 reported records.
Alexion Pharmaceuticals, Inc. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $205.14 | 28.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.45 | 23.0% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $83.58 | 11.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.91 | 8.9% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.72 | 6.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.65 | 4.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.50 | 4.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.61 | 4.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.08 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.90 | 2.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.03 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.60 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $732.17 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.44 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $83.58 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.89 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.84 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
46 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 53 |
| Lisinopril | Lisinopril | 177 | 52 |
| Losartan Potassium | Losartan Potassium | 170 | 50 |
| Furosemide | Furosemide | 161 | 49 |
| Omeprazole | Omeprazole | 138 | 39 |
| Alprazolam | Alprazolam | 135 | 24 |
| Gabapentin | Gabapentin | 122 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 37 |
| Ezetimibe | Ezetimibe | 114 | 32 |
| Eliquis | Apixaban | 101 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 29 |
| Metformin Hcl | Metformin Hcl | 100 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 31 |
| Montelukast Sodium | Montelukast Sodium | 85 | 26 |
| Simvastatin | Simvastatin | 79 | 24 |
| Allopurinol | Allopurinol | 77 | 20 |
| Sertraline Hcl | Sertraline Hcl | 76 | 19 |
| Pregabalin | Pregabalin | 75 | 16 |
| Jardiance | Empagliflozin | 72 | 16 |
| Carvedilol | Carvedilol | 70 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 17 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Trazodone Hcl | Trazodone Hcl | 58 | 16 |
| Prednisone | Prednisone | 57 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Spironolactone | Spironolactone | 53 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Atenolol | Atenolol | 51 | 11 |
| Celecoxib | Celecoxib | 50 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Donepezil Hcl | Donepezil Hcl | 49 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 46 |
| Clonazepam | Clonazepam | 46 | 13 |
| Famotidine | Famotidine | 46 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 11 |
| Irbesartan | Irbesartan | 44 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 14 |
| Lovastatin | Lovastatin | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 11 |
| Colchicine | Colchicine | 33 | 14 |
| Baclofen | Baclofen | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Glipizide | Glipizide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Finasteride | Finasteride | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $732.17 · 32 records | Alexion Pharmaceuticals, Inc. | Dexcom G6 Transmitter, JARDIANCE, Korlym, NURTEC ODT, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error